Circumventing P-Glycoprotein-Mediated Cellular Efflux of Quinidine by Prodrug Derivatization
Authors:
- 15 June 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 1 (4) , 290-299
Abstract
The objective of this study is to investigate whether transporter-targeted prodrug derivatization of quinidine, a model P-glycoprotein (P-gp) substrate, can circumvent P-gp-mediated efflux. The l-valine ester of quinidine (val-quinidine) was synthesized in our laboratory. Uptake and transport studies were carried out using the MDCKII-MDRI cell line at 37 °C for 10 min and 3 h, respectively. [3H]Ritonavir and cyclosporine were also used as model P-gp substrates to delineate the kinetics of translocation of val-quinidine across the MDCKII-MDRI cell monolayer. The rate of uptake of [3H]ritonavir by MDCKII-MDRI cells exhibited a 2-fold increase in the presence of 75 μM quinidine, but 75 μM val-quinidine did not demonstrate any effect on [3H]ritonavir uptake. The rate of transport of quinidine from the basolateral to the apical membrane [(18.3 ± 1.25) × 10-6 cm s-1] and from the apical to the basolateral membrane [(6.5 ± 0.66) × 10-6 cm s-1] exhibited a 3-fold difference. However, transport of val-quinidine from the apical to the basolateral membrane [(5.13 ± 0.49) × 10-6 cm s-1] and from the basolateral to the apical membrane [(6.17 ± 1.28) × 10-6 cm s-1] did not demonstrate any statistically significant difference. Moreover, cyclosporine, a potent P-gp substrate and/or inhibitor, did not alter the transport kinetics of val-quinidine. The rates of uptake of [3H]Gly-Sar and various amino acid model substrates were reduced in the presence of 200 μM val-quinidine. Results from this study clearly indicate that prodrug derivatization of quinidine into val-quinidine can overcome P-gp-mediated efflux. Val-quinidine once bound to a peptide or amino acid transporter is probably not recognized and cannot be accessed by the P-gp efflux pump. Transporter-targeted prodrug derivatization seems to be a viable strategy for overcoming P-gp-mediated efflux. Keywords: Efflux; prodrug; P-glycoprotein; val-quinidineKeywords
This publication has 26 references indexed in Scilit:
- P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancementPharmacological Research, 2003
- Transporter-Mediated Permeation of Drugs Across the Blood–Brain BarrierJournal of Pharmaceutical Sciences, 2000
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Structure, Function, and Molecular Modeling Approaches to the Study of the Intestinal Dipeptide Transporter PepT1Journal of Pharmaceutical Sciences, 1998
- The barrier function of CYP3A4 and P-glycoprotein in the small bowelAdvanced Drug Delivery Reviews, 1997
- Carrier-Mediated Intestinal Transport of DrugsPharmaceutical Research, 1996
- ATP-DEPENDENT TRANSPORT SYSTEMS IN BACTERIA AND HUMANS: Relevance to Cystic Fibrosis and Multidrug ResistanceAnnual Review of Microbiology, 1993
- Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicityInternational Journal of Cancer, 1992
- Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Proceedings of the National Academy of Sciences, 1989
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences, 1987